Muna Therapeutics Market Research Report
Company Overview
Name
Muna Therapeutics
Mission of the Company
Muna Therapeutics is focused on discovering and developing therapies that slow or stop devastating neurodegenerative diseases, including Alzheimer’s and Parkinson’s disease.
Founding Information
- When was the company founded and by whom: No information is available
- Key people in the company:
- Rita Balice-Gordon, PhD - Chief Executive Officer
- Anders Hinsby, PhD - Chief Operating Officer
- Niels Plath, PhD - Chief Scientific Officer
- Jakob Busch-Petersen, PhD - Chief Development Officer
- Pernille Aasholm - Head of People
- Elizabeth Birch, PhD - Head of Business Development
- Manuela Polydoro, PhD - Head of Translational Medicine
- Lars Christian Roenn, PhD - Head of Preclinical Biology
- Joachim Vilstrup, PhD - Head of Protein Chemistry and Structural Biology
- Maria Dalby, PhD - Head of Bioinformatics
- Wei-Ting Chen, PhD - Head of Discovery Biology
- Heleen Verlinden, PhD - Head of Operations, Leuven and Program Management
- Peter Flagstad, PhD - Program Head
- Kim Andersen, PhD - Program Head
- Donald Nicholson - Independent Chair of Board of Directors
Headquarters
- Where is the company headquartered: Copenhagen, Denmark and Boston, US
Number of Employees
No information is available
Revenue
No information is available
What is the company known for
Muna Therapeutics is recognized for its groundbreaking work in developing therapies that aim to preserve cognition and other brain functions, enhance resilience to disease pathology, and slow or stop the progression of neurodegenerative diseases.
Products
What products do they offer
Muna Therapeutics offers small molecule drug discovery programs focused on treating neurodegenerative diseases.
High-level description of the product and key features
1. TREM2 Agonism for Alzheimer’s Disease:
- Description: This program focuses on early-stage Alzheimer’s Disease and aims to activate TREM2, a key signaling molecule in microglial cells.
- Key Features: Small molecule agonists with high selectivity and potency, capable of enhancing microglial function to clear pathological hallmarks of Alzheimer’s Disease.
2. Kv1.3 Blockade for Parkinson’s Disease and Multiple Sclerosis:
- Description: This program targets the Kv1.3 potassium channel, known to regulate microglial reactivity and inflammatory responses.
- Key Features: Small molecules with high selectivity and potency that aim to block Kv1.3, reduce neuroinflammation, and protect neurons from degeneration.
Recent Developments
Recent Grants and Appointments
- October 11, 2022: Muna Therapeutics was awarded a $4.9M grant from The Michael J. Fox Foundation for Parkinson’s Research. This grant will support the development of disease-modifying therapy for Parkinson’s Disease.
- November 1, 2021: Dr. Niels Plath was appointed as Chief Scientific Officer.
- September 13, 2021: Dr. Donald Nicholson was appointed as Independent Chair of the Board of Directors.
New Product Launches
No information is available
New Features Added to Existing Products
No information is available
New Partnerships
No information is available
© 2023 Muna Therapeutics